Tecovirimat
Cat.No:IT3050 Solarbio
CAS:869572-92-9
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥90%
Appearance:Solid
Qty:
Size:
{{cart_num}}
My CartCAS:869572-92-9
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥90%
Appearance:Solid
Qty:
Size:
CAS | 869572-92-9 |
Name | Tecovirimat |
Molecular Formula | C19H15F3N2O3 |
Molecular Weight | 376.33 |
Solubility | Soluble in DMSO(Need ultrasonic) |
Purity | ≥90% |
Appearance | Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
SMILES | C1C2C1C3C=CC2C4C3C(=O)N(C4=O)NC(=O)C5=CC=C(C=C5)C(F)(F)F |
InChIKey | CSKDFZIMJXRJGH-VWLPUNTISA-N |
InChI | InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+ |
PubChem CID | 16124688 |
Target Point | Antiviral |
Passage | Anti-infection |
Background | It is an Antiviral compound that can inhibit the release of orthopoxviruses by targeting p37 protein orthologs, and can be used in related studies to treat smallpox infection. |
Biological Activity | Tecovirimat 是一种口服生物活性抗痘病毒化合物,对多种正痘病毒具有强效和选择性活性,EC50 约为 10 nM。[1-2] |
In Vitro | Tecovirimat is potent(concentration that inhibited virus replication by 50% = 0.010 microM),selective(concentration of compound that inhibited cell viability by 50% = >40 microM),and active against multiple orthopoxviruses,including vaccinia,monkeypox,camelpox,cowpox,ectromelia(mousepox),and variola viruses. In cell culture,tecovirimat inhibited plaque formation and virus-induced cytopathic effects. In single-cycle growth assays,tecovirimat reduced extracellular virus formation by 10 fold relative to untreated controls,while having little effect on the production of intracellular virus.[1] Tecovirimat against cowpox virus(CV),vaccinia virus(VV),and ectromelia virus(ECTV)and had an in vitro 50% effective concentration(EC50)of 0.48 microM against CV,0.05 microM against VV,and 0.07 microM against ECTV.[2] |
In Vivo | In vivo oral administration of tecovirimat protected BALB/c mice from lethal infection,following intranasal inoculation with 10x 50% lethal dose(LD(50))of vaccinia virus strain IHD-J. Orally administered tecovirimat also protected A/NCr mice from lethal infection,following intranasal inoculation with 40,000x LD(50)of ectromelia virus. Oral administration of tecovirimat inhibited vaccinia virus-induced tail lesions in mice inoculated via the tail vein.[1] Tecovirimat(10-100mg/kg/d; 14-day; oral)administered to mice infected intranasally with CV significantly reduce mortality. Tecovirimat(100mg/kg/d; 5days)was administered to VV-infected mice significantly reduce mortality. Tecovirimat(10-100mg/kg/d; 10 days; oral)can prevent death in mice infected with ECTV.[2] |
Data Literature Source | [1]. Yang G,et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol. 2005 Oct;79(20):13139-49. [2]. Quenelle DC,et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother. 2007 Feb;51(2):689-95. |
Unit | Bottle |
Specification | 1mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.